Hua Medicine is a Shanghai-based, clinical-stage drug development company focused on novel therapies for Type 2 diabetes and levodopa-induced dyskinesia in Parkinson’s disease. The company has worldwide rights to two novel assets, the most advanced being dorzagliatin (HMS5552). Dorzagliatin is described as a first-in-class, 4th-generation glucokinase activator that aims to treat impaired blood glucose sensor function. The drug is in two Phase III trials in China: a monotherapy study and a combination therapy study with metformin. Hua announced a combined Series D & Series E financing intended to fully fund completion of those Phase 3 trials and a commercial launch in China. The company was founded by entrepreneurs and international investment firms and positions dorzagliatin as a potential disease-modifying treatment for Type 2 diabetes. Hua Medicine is a clinical-stage, innovative drug development company focused on novel therapies for the treatment of diabetes and central nervous system disorders. Its lead program is HMS5552, a new 4th-generation glucokinase activator (GKA) for type 2 diabetes. The company plans to use the new financing to complete long-term Phase 2 clinical trials and to accelerate Phase 3 development of HMS5552, alongside advancing additional novel assets in its pipeline. Hua is led by CEO Li Chen and is based in Shanghai, China. It expects to finish a multicenter, 12-week Phase 2 trial of HMS5552 in diabetic patients by mid-year, with topline results available by the end of 2016. Hua Medicine is a Shanghai, China–based clinical-stage biotech led by Dr. Li Chen developing novel therapies for Type 2 diabetes and CNS disorders. Its most advanced program is HMS5552 (Sinogliatin), an oral 4th‑generation glucokinase activator (GKA) about to enter Phase 2 trials in China. The company has also internally developed earlier-stage CNS compounds targeting a validated CNS target for indications including Parkinson’s disease–associated dyskinesia and depressive disorder. Hua recently closed a $25M Series B to fund clinical and preclinical programs. Planned uses of proceeds include catalyzing Phase 2 development of HMS5552, advancing GKA therapies in the U.S., developing an IND candidate for a novel CNS asset, and sponsoring long‑term preclinical studies to prepare for future Phase 3 trials.

Total raised

$192M

Funding rounds

3

Latest round

Series D

Latest activity

Mar 2018